LOGISTICS SUPPORT OF CSR ACTIVITIES IN THE GLOBAL SUPPLY CHAINS OF THE PHARMACEUTICAL SECTOR
KeywordsCSR, pharmaceutical industry, logistics, logistics service
Purpose: Research paper identifies the current trends in the logistics support of the global pharmaceutical industry, including CSR activities. Research results can be a good reference point for decision-makers in the fields of logistics management. The subject matter of the paper is based mainly on the comparison of logistics practices in the area of CSR in the pharmaceutical industry supply chains.
Methodology: To achieve the research goal stated for this study, two research procedures were chosen and implemented:1) documents review (triangulation of sources); 2) literature review with the use of Boolean logic and the chosen procedure, valid for socio-economic research.
Findings: This paper points out that the set of methods and tools used in logistics support of the CSR activities overlap in some part the set of methods and tools for core business activity (commercial sales of medicines).
Implications for practice: Research results can be a good reference point for decision-makers in the fields of logistics management and CSR of the pharmaceutical industry.
Originality/value: This paper is the first about logistics support of CSR activities in the pharmaceutical industry. It shows the similarities and differences between the support of the basic, primary activities and CSR ones. It can be the basis for further theoretical and empirical research.
Adobor, H. (2012), “Ethical Issues in Outsourcing: The Case of Contract Medical Research and the Global Pharmaceutical Industry”, Journal of Business Ethics, Vol. 105 No. 2, pp. 239-255.
Alexandra Countess of Frederiksborg, Fort, T.L. (2014), “The paradox of pharmaceutical CSR: The sincerity nexus”, Business Horizons, Vol. 57, pp. 151-160.
Azim, M.I., Azam, S. (2013), Corporate Sustainability Reporting by Pharmaceutical Companies: is it what it seems to be?”, Corporate Ownership & Control, Vol. 11 No. 1, pp. 754-765.
aus der Beek, T., Weber, F. A., Bergmann, A., Hickmann, S., Ebert, I., Hein, A., Küster, A. (2016), „Pharmaceuticals in the environment - Global occurrences and perspectives”, Environmental Toxicology and Chemistry, Vol. 35 No. 4, pp. 823-835.
Carroll, A.B. (2008), “A history of corporate social responsibility. Concepts and practices.” in: Crane, A., Matten, D., McWillams, A., Siegel, D.S. (Eds.) The Oxford Handbook of Corporate Social Responsibility, Oxford, UK, pp. 34-42.
Droppert, H., Bennett, S. (2015), “Corporate social responsibility in global health: an exploratory study of multinational pharmaceutical firms”, Globalization and Health, Vol. 11 No. 15, pp. 1-8.
Dyllick, T., Hockerts, K. (2002), "Beyond the business case for corporate sustainability", Business Strategy and the Environment, Vol. 11 No. 2, pp. 130-141.
“Eisai Pharma gets award for CSR activity” (2014), Chemical Business, January, p. 57.
Elkington, J. (1998), “Partnership from cannibals with forks: The triple bottom line of 21st-centry business”, Environmental Quality Management, Vol. 8 No. 1, pp. 37-51.
Enyinda, I.C., Briggs, C., Bachkar, K. (2009), “Managing risk in pharmaceutical global supply chain outsourcing: applying Analytic Hierarchy Process model”, American Society of Business and Behavioral Sciences Las Vegas, Vol. 16 No. 1, pp. 1-15.
France, N., Bureana, E. (2015), “History of Corporate Social Responsibility Concept”. Annales Universitatis Apulensis Series Oeconomica, Vol. 17 No. 2, pp. 30-36.
Friemann, F., Schönsleben, P. (2013), “Global Logistics Excellence and Best Practices in Pharma: Results from an interview series with 11 large, multinational pharmaceutical companies”, available at: https://www.research-collection.ethz.ch/, pp. 1-48 (accessed 10 January 2019).
Givel, M. (2013), “Modern Neoliberal Philanthropy: motivations and impact of Pfizer Pharmaceutical’s corporate social responsibility campaign”, Third World Quarterly, Vol. 34 No. 1, pp. 171-182.
Göpfert, I., Stephan, M., Wellbrock, W., Ackermann, M. (2013), “An Empirical Analysis of the Board Composition Concerning Logistics Competencies”, World Academy of Science, Engineering and Technology International Journal of Mechanical and Industrial Engineering, Vol. 7 No. 3, pp. 602-608.
Gray, J.V., Roth, A.V., Leiblein, M.J. (2011), “Quality risk in offshore manufacturing: Evidence from the pharmaceutical industry”, Journal of Operations Management, Vol. 29 No. 7, pp. 737-752.
Greve, J. (2008), “Healthcare in developing countries and the role of business: a global governance framework to enhance the accountability of pharmaceutical companies”, Corporate Governance: The International Journal of Business in Society, Vol. 8 No. 4, pp. 490-505.
Grover, A., Citro, B., Mankad, M., Lander, F. (2012), “Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health”, Journal of Law Medicine and Ethics, Vol. 40 No. 2, pp. 234-250.
Harrington, T.S., Phillips, M.A., Singh Srai, J. (2017), “Reconfiguring global pharmaceutical value networks through targeted technology interventions”, International Journal of Production Research, Vol. 55 No. 5, pp. 1471-1487.
Khaleel, M., Chelliah, S., Rauf, S., Jamil, M. (2017), "Impact of perceived corporate social responsibility on attitudes and behaviors of pharmacists working in MNCs", Humanomics, Vol. 33 No. 4, pp. 453-469.
Khan, Z., Lew, Y.K., Park, B.I. (2015), "Institutional legitimacy and norms-based CSR marketing practices: Insights from MNCs operating in a developing economy", International Marketing Review, Vol. 32 No. 5, pp. 463-491.
Lau, A.K.W., Lee P.K.C., Cheng, T.C.E. (2018), “An empirical taxonomy of corporate social responsibility in China's manufacturing industries”, Journal of Cleaner Production, Vol. 188, pp. 322-338.
Lee, P.K.C., Lau, A.K.W., Cheng, T.C.E., “Employee rights protection and financial performance”, Journal of Business Research, Vol. 66 No. 10, pp. 1861-1869.
Leisinger, K.M. (2005), “The Corporate Social Responsibility of the Pharmaceutical Industry: Idealism without Illusion and Realism without Resignation”, Business Ethics Quarterly, Vol. 15 No. 4, pp. 579-592.
Luo, X., Zheng, Q. (2013), “Reciprocity in Corporate Social Responsibility and Channel Performance: Do Birds of a Feather Flock Together?”, Journal of Business Ethics, Vol. 118 No. 1, pp. 203-213.
Martinuzzi, A., Krumay, B., Pisano, U. (2011), “Focus CSR: The New Communication of the EU Commission on CSR and National CSR Strategies and Action Plans”, European Sustainable Development Network, available at: https://www.researchgate.net/publication/267801215_Focus_CSR_The_New_Communication_of_the_EU_Commission_on_CSR_and_National_CSR_Strategies_and_Action_Plans (accessed 10 January 2019).
Matten, D., Moon, J. (2005), “A Conceptual Framework for Understanding CSR”, in: Habisch, A., Jonker, J., Wegner, M., Schmidtpeter, R. (Eds.), Corporate Social Responsibility Across Europe, Springer Berlin, Heidelberg.
Mehralian, G., Nazari, J.A., Zarei, L., Rasekh, H.R. (2016), “The effects of corporate social responsibility on organizational performance in the Iranian pharmaceutical industry: The mediating role of TQM”, Journal of Cleaner Production, Vol. 135, pp. 689-698.
Min, M., Desmoulins-Lebeault, F., Esposito, M. (2017), “Should pharmaceutical companies engage in corporate social responsibility?”, Journal of Management Development, Vol. 36 No. 1, pp. 58-70.
Mousazadeh, M., Torabi, S.A., Zahiri, B. (2015), “A robust possibilistic programming approach for pharmaceutical supply chain network design”, Computers and Chemical Engineering, Vol. 82, pp. 115-128.
Murphy, P.E. (1978), “An Evolution: Corporate Social Responsiveness”, University of Michigan Business Review, November.
O’Riordan, L., Fairbrass, J. (2014), “Managing CSR Stakeholder Engagement: A New Conceptual Framework”, Journal of Business Ethics, Vol. 125, pp. 121-145.
OECDC (2017), “World Drug Report 2017”, available at: https://www.unodc.org/wdr2017/index.html (accessed 14 January 2019).
Rehman, M.S.U., Rashid, N., Ashfaq, M., Saif, A., Ahmad, N., Han, J.-I. (2015), “Global risk of pharmaceutical contamination from highly populated developing countries”, Chemosphere, Vol. 138, pp. 1045-1055.
Shaw, B., Whitney, P. (2016), “Ethics and compliance in global pharmaceutical industry marketing and promotion: The role of the IFPMA and self-regulation”, Pharmaceuticals Policy and Law, Vol. 18, pp. 199-206.
Smith, A.D. (2008), “Corporate social responsibility practices in the pharmaceutical industry”, Business Strategy Series, Vol. 9 No. 6, pp. 306-315.
Sousa, R.T., Liu, S., Papageorgiou, L.G., Shah, N. (2011), “Global supply chain planning for pharmaceuticals”, Chemical Engineering Research and Design, Vol. 89, pp. 2396-2409.
Statista (2017), “Medicine Spending Worldwide”, available at: https://www.statista.com/statistics/280572/medicine-spending-worldwide/ (accessed 28 January 2019).
Steurer, R., Langer, M.E., Konrad, A., Martinuzzi, A. (2005), “Corporations, stakeholders and sustainable development I: a theoretical exploration of business society relations”, Journal of Business Ethics, Vol. 61 No. 3, pp. 263-281.
Sturchio, J.L. (2008), “Business engagement in public programs: the pharmaceutical industry's contribution to public health and the millennium development goals”, Corporate Governance: The International Journal of Business in Society, Vol. 8 No. 4, pp. 482-489.
Susarla, N., Karimi, I.A. (2012), “Integrated supply chain planning for multinational pharmaceutical enterprises”, Computers and Chemical Engineering, Vol. 42, pp. 168-177.
Szmelter, A. (2019), “Global Pharmaceutical Industry: Characteristics and Trends”, in: Nozari, H., Szmelter, A. (Eds.), Global Supply Chains in the Pharmaceutical Industry, IGI Global, Hershey, Pennsylvania, USA, pp. 57-85.
Teker, S.C. (2017), “The Implementation of Analytic Hierarchy Process in Pharmaceutical Industry for Selection Process of 3rd Party Logistics Service Provider”, Öneri, Vol. 12 No. 48, pp. 107-124.
Tempest, B. (2010), “A structural change in the global pharmaceutical marketplace”, Journal of Generic Medicines, Vol. 7 No. 2, pp. 113-117.
Thorsteinsdóttir, H., Ovtcharenko, N., Kohler, J.C. (2017), “Corporate social responsibility to improve access to medicines: the case of Brazil”, Globalization and Health, Vol. 13 No. 10, pp. 1-11.
Toma, S.-G., Marinescu, P. (2012), “Business Models Based on Corporate Social Responsibility: the Case of Global Pharmaceutical Companies”, Ovidius University Annals. Economics Sciences Series, Vol. XII No. 1, pp. 1221-1225.
Tranfield, D., Denyer, D., Smart, P. (2003), “A systematic review of literature on offshoring of value chain activities”, British Journal of Management, Vol. 14 No. 3, pp. 207-222.
Valverde J.-L. (2012), “Corporate responsibility and pharmaceutical fraud”, Pharmaceuticals Policy and Law, Vol. 14, pp. 129-156.
Vian, T., McCoy, K., Richards, S.C., Connelly, P., Feeley, F. (2007), “Corporate Social Responsibility in Global Health: The Pfizer Global Health Fellows International Volunteering Program”, Human Resource Planning, Vol. 30.1, pp. 30-35.
Witty, A. (2011), “New Strategies For Innovation In Global Health: A Pharmaceutical Industry Perspective”, Health Affairs, Vol. 30 No. 1, pp. 118-126.
How to Cite
Articles submitted to the journal should not have been published before in their current or substantially similar form, or be under consideration for publication with another journal. Authors submitting articles for publication warrant that the work is not an infringement of any existing copyright and will indemnify the publisher against any breach of such warranty. For ease of dissemination and to ensure proper policing of use, papers and contributions become the legal copyright of the publisher unless otherwise agreed.
Plagiarism and ghostwriting
In response to the issue of plagiarism and ghostwriting the editors of the Journal of Positive Management has introduced the following rules to counteract these phenomena:
1. Contributors should be aware of their responsibility for a content of manuscripts.
2. Collective authors are obliged to reveal the contribution and an affiliation of each author (i.e. who is an author of specified part of a paper).
3. Any act of dishonesty will be denounced, the editors will inform appropriate institutions about the situation and give evidence of all cases of misconduct and unethical behaviour.
4. The editors may ask contributors for financial disclosure (i.e. contribution of specified institutions).
Number of views and downloads: 9
Number of citations: 0